Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management

Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197], JAMA, 289, 2560, 10.1001/jama.289.19.2560 American Diabetes Association, 2008, Standards of medical care in diabetes—2008, Diabetes Care, 31, S12, 10.2337/dc08-S012 Berry, 2007, Coronary heart disease in patients with diabetes: Part I: Recent advances in prevention and noninvasive management, J Am Coll Cardiol, 49, 631, 10.1016/j.jacc.2006.09.046 Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405 Adler, 2000, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study [published correction appears in BMJ. 2001;322:90], BMJ, 321, 412, 10.1136/bmj.321.7258.412 Holman, 2008, Long-term follow-up after tight control of blood pressure in type 2 diabetes, N Engl J Med, 359, 1565, 10.1056/NEJMoa0806359 Gotto, 2007, Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus, Am J Cardiol, 99, 3B, 10.1016/j.amjcard.2006.11.001 Alexander, 2003, NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Buse, 2007, Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association, Diabetes Care, 30, 162, 10.2337/dc07-9917 AACE Diabetes Mellitus Clinical Practice Guidelines Task Force, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Saaddine, 2006, Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002, Ann Intern Med, 144, 465, 10.7326/0003-4819-144-7-200604040-00005 Saydah, 2004, Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes, JAMA, 291, 335, 10.1001/jama.291.3.335 National Committee for Quality Assurance, 2007 Bodenheimer, 2007, A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans, JAMA, 298, 2048, 10.1001/jama.298.16.jrr70000 Consensus Committee, 2007, Diabetes Care, 30, 2399, 10.2337/dc07-9925 Action to Control Cardiovascular Risk in Diabetes Study Group, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 LeRoith, 2005, Monitoring glycemic control: The cornerstone of diabetes care, Clin Ther, 27, 1489, 10.1016/j.clinthera.2005.10.010 Wood Fonseca, 2007, Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus, Am J Med, 120, S18, 10.1016/j.amjmed.2007.07.004 Fonseca, 2004, Nontraditional risk factors for cardiovascular disease in diabetes, Endocr Rev, 25, 153, 10.1210/er.2002-0034 Muntner, 2004, Ann Epidemiol, 14, 686, 10.1016/j.annepidem.2004.01.002 Sobel, 2007, Optimizing cardiovascular outcomes in diabetes mellitus, Am J Med, 120, S3, 10.1016/j.amjmed.2007.07.002 UK Prospective Diabetes Study (UKPDS) Group, 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558], Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 Holman, 2008, 10-Year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470 Mazzone, 2007, Prevention of macrovascular disease in patients with diabetes mellitus: Opportunities for intervention, Am J Med, 120, S26, 10.1016/j.amjmed.2007.07.005 Dormandy, 2005, Secondary prevention of macro-vascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Erdmann, 2007, The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) study, J Am Coll Cardiol, 49, 1772, 10.1016/j.jacc.2006.12.048 Inzucchi, 2005, Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project, Diabetes Care, 28, 1680, 10.2337/diacare.28.7.1680 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100], N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 Cefalu, 2008, Intensive glycemic control and cardiovascular disease observations from the ACCORD study: Now what can a clinician possibly think?, Diabetes, 57, 1163, 10.2337/db08-0220 Centers for Disease Control and Prevention Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med, 353, 2643, 10.1056/NEJMoa052187 Eguchi, 2006, Impact of blood pressure vs. glycemic factors on target organ damage in patients with type 2 diabetes mellitus, J Clin Hypertens (Greenwich), 8, 404, 10.1111/j.1524-6175.2006.04739.x Eguchi, 2007, Masked hypertension in diabetes mellitus: A potential risk, J Clin Hypertens (Greenwich), 9, 601, 10.1111/j.1524-6175.2007.06610.x Leitão, 2007, Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients, Diabetes Care, 30, 1255, 10.2337/dc06-2131 Stone, 2005, Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options, Am J Cardiol, 96, 53E, 10.1016/j.amjcard.2005.06.006 Jensen, 2007, What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?, Am J Med, 120, S25, 10.1016/j.amjmed.2007.06.011 Jensen, 2006, Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors, Obesity (Silver Spring), 14, 143S, 10.1038/oby.2006.294 Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet. 2006;368:1650], Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8 Addy, 2008, The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake, Cell Metab, 7, 68, 10.1016/j.cmet.2007.11.012 Nissen, 2008, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial, JAMA, 299, 1547, 10.1001/jama.299.13.1547 Fong, 2007, Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents, J Pharmacol Exp Ther, 321, 1013, 10.1124/jpet.106.118737 Doggrell, 2005, Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?, Exp Opin Invest Drugs, 14, 339, 10.1517/13543784.14.3.339